Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VOGUE: Dolutegravir/Lamivudine vs Bictegravir/Emtricitabine/Tenofovir Alafenamide in ART-Naive Adults with HIV
NCT05979311Phase 3Active, not recruiting
- Sponsor
- ViiV Healthcare
- Start
- Feb 2024
- Primary completion
- Apr 2026
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 17
01
Overview
Phase 3, randomised, open-label trial of dolutegravir and lamivudine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by ViiV Healthcare. Primary endpoint: Percentage of participants with plasma HIV-1 RNA <50 copies/mL at 48 weeks. Started Feb 2024; status: active, not recruiting.
02
Drugs
dolutegravirlamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05979311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05979311.